First-Line Sacituzumab Tirumotecan Combo Improves Advanced NSCLC Outcomes
The confirmed ORR was 40.0% in cohort 1A and 66.7% in cohort 1B of patients treated with sacituzumab tirumotecan/tagitanlimab for advanced NSCLC.
Previous Post
FDA Approves First RNA-Targeted Treatment for Hereditary Angioedema
Next Post
Preventive Cardiology Through Fresh Eyes: Highlights From ASPC’s 2025 Congress
📢
Advertisement
300x250 Banner
Recent Content
COPD Biologics: Early Treatment Insights
Pulmonology • 2 hours ago
Antihypertensive Medication Guidelines
Cardiology • 4 hours ago
Juvenile Arthritis Care Transition
Rheumatology • 6 hours ago